To evaluate the efficacy and safety of once-weekly DPP-4 inhibitor: Omarigliptin and the differences between Omarigliptin and once or twice-daily DPP-4 inhibitors for the treatment of type 2 diabetes

To evaluate the efficacy and safety of once-weekly DPP-4 inhibitor: Omarigliptin and the differences between Omarigliptin and once or twice-daily DPP-4 inhibitors for the treatment of type 2 diabetes - To evaluate the efficacy of Omarigliptin and the differences between Omarigliptin and daily DPP-4 inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029288

Enrollment

Registered

2017-09-29

Start date

2017-09-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Active treatment with Omarigliptin 25mg once-weekly for 12 months Active treatment with Daily-DPP4 inhibitor for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients

Exclusion criteria

Exclusion criteria: 1)eGFR<30 2)Having had side effects of another DPP-4inhibitors before

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose and IRI are set to be measured at baseline, 3, 6, 9, 12 months.	—

Secondary

Measure	Time frame
Body mas index (BMI), blood pressure, albumin-creatinine ratio (ACR), lipid and liver function are set to be measured at baseline, 3, 6, 9, 12 months	—

Countries

Japan

Contacts

Public ContactSachiko Hattori

Foundation Health Medicine Association Tohto Clinic Diabetes Internal Medicine

s-hattori@kenkoigaku.or.jp03-3239-0301

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026